Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.

Abstract

In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine.

• Authors: Wen Zhang, Chenman Qin, Yunyun Fei, Min Shen, Yangzhong Zhou, Yan Zhang, Xiaofeng Zeng, Shuyang Zhang
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 239 Pg. 109022 (06 2022) ISSN: 1521-7035 [Electronic] United States
• PMID: 35477027 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022. Published by Elsevier Inc.

Chemical References

• Anti-Inflammatory Agents
• Hydroxychloroquine
• Chloroquine

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Chloroquine (therapeutic use)
• Humans
• Hydroxychloroquine (therapeutic use)
• SARS-CoV-2
• COVID-19 Drug Treatment